
Caris Life Sciences Launches PTEN Testing for Metastatic Prostate Cancer
Caris Life Sciences is integrating PTEN immunohistochemistry testing into its clinical menu, aiming to identify patients with metastatic androgen pathway modulation-sensitive prostate cancer. This diagnostic expansion follows the recent FDA approval of capivasertib, offering a biomarker-driven path for individuals whose tumors exhibit specific protein loss.

























